Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Demand for Clinical Trials
4.2.2 High R&D Expenditure of the Pharmaceutical Industry
4.2.3 Rising Prevalence of Diseases
4.3 Market Restraints
4.3.1 Lack of Skilled Workforce for Clinical Research
4.3.2 Stringent Regulations
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Design
5.2.1 Treatment Studies
5.2.1.1 Randomized Control Trial
5.2.1.1.1 Double Blind Trial Randomized Trial
5.2.1.1.2 Single Blind Trial Randomized Trial
5.2.1.1.3 Non-blind Randomized Trial
5.2.1.2 Adaptive Clinical Trial
5.2.1.3 Non-randomized Control Trial
5.2.2 Observational Studies
5.2.2.1 Cohort Study
5.2.2.2 Case Control Study
5.2.2.3 Cross Sectional Study
5.2.2.4 Ecological Study
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Clinipace
6.1.2 Eli Lilly and Company
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 ICON PLC
6.1.5 IQVIA
6.1.6 Laboratory Corporation of America
6.1.7 Novo Nordisk AS
6.1.8 PAREXEL International Corporation
6.1.9 Pfizer Inc.
6.1.10 Pharmaceutical Product Development LLC


7 MARKET OPPORTUNITIES AND FUTURE TRENDS